Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefotaxime
Drug ID BADD_D00390
Description Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Indications and Usage Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
Marketing Status approved
ATC Code J01DD01
DrugBank ID DB00493
KEGG ID D07647
MeSH ID D002439
PubChem ID 5742673
TTD Drug ID D0D1HA
NDC Product Code 0143-9933; 0143-9931; 0143-9935; 0143-9930
UNII N2GI8B1GK7
Synonyms Cefotaxime | Cephotaxim | Cefotaxim | Biosint | Cefotaxime Sodium | Sodium, Cefotaxime | Cefradil | Taporin | Fotexina | HR-756 | HR 756 | HR756 | Kendrick | Ru-24756 | Ru 24756 | Ru24756 | Benaxima | Claforan | Primafen | Klaforan
Chemical Information
Molecular Formula C16H17N5O7S2
CAS Registry Number 63527-52-6
SMILES CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.0010.000097%
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.0020.000073%Not Available
Pyrexia08.05.02.0030.000267%
Rash23.03.13.0010.000170%Not Available
Rash erythematous23.03.13.0290.000049%Not Available
Rash maculo-papular23.03.13.0040.000146%
Rash papular23.03.13.0170.000049%Not Available
Renal failure20.01.03.005--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000049%
Seizure17.12.03.0010.000073%
Shock24.06.02.0020.000049%Not Available
Sinus bradycardia02.03.03.0090.000049%
Skin exfoliation23.03.07.0030.000049%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000049%Not Available
Somnolence19.02.05.003; 17.02.04.0060.000049%
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Sudden death08.04.01.003; 02.03.04.0130.000049%
Superinfection11.01.08.009--Not Available
Syncope17.02.04.008; 02.11.04.015; 24.06.02.0120.000073%
Tachycardia02.03.02.0070.000049%Not Available
Tenderness08.01.08.005--Not Available
Thrombocytopenia01.08.01.0020.000073%Not Available
Torsade de pointes02.03.04.0050.000073%Not Available
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015--
Urticaria23.04.02.001; 10.01.06.0010.000049%
Urticaria aquagenic23.04.02.006; 10.01.06.006--Not Available
Vaginal infection11.01.10.002; 21.14.02.002--
Vasculitis24.12.04.027; 10.02.02.0060.000049%
Vomiting07.01.07.0030.000122%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene